Boston Scientific Corp
BSX92.190USD
-0.390-0.42%
Handelsschluss 12/15, 16:00（ET）Kurse um 15 Minuten verzögert
136.65BMarktkapitalisierung
48.83KGV TTM
mehr Informationen über Boston Scientific Corp Unternehmen
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Boston Scientific Corp Informationen
BörsenkürzelBSX
Name des UnternehmensBoston Scientific Corp
IPO-datumMay 19, 1992
CEOMahoney (Michael F)
Anzahl der mitarbeiter53000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 19
Addresse300 Boston Scientific Way
StadtMARLBOROUGH
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl01752-1234
Telefon15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
BörsenkürzelBSX
IPO-datumMay 19, 1992
CEOMahoney (Michael F)
Führungskräfte von Boston Scientific Corp
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
41.58K
+5.27%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.29K
+1.62%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
24.13K
-34.82%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
5.63K
+58.67%
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.08K
-58.23%
Mr. Arthur Crosswell Butcher
Mr. Arthur Crosswell Butcher
Executive Vice President, Group President, MedSurg and Asia Pacific
Executive Vice President, Group President, MedSurg and Asia Pacific
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.75M
-3.25%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
+3.95%
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
41.58K
+5.27%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
35.29K
+1.62%
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
33.45K
+6.64%
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
24.13K
-34.82%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Electrophysiology
840.00M
16.60%
Endoscopy
737.00M
14.56%
Interventional Cardiology Therapies
731.00M
14.44%
Peripheral Interventions
698.00M
13.79%
Urology
676.00M
13.36%
Andere
1.38B
27.25%
Nach RegionUSD
Name
Umsatz
Anteil
United States
3.22B
63.70%
EMEA (Europe, Middle East and Africa)
878.00M
17.35%
Asia Pacific
790.00M
15.61%
Latin America and Canada
169.00M
3.34%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Electrophysiology
840.00M
16.60%
Endoscopy
737.00M
14.56%
Interventional Cardiology Therapies
731.00M
14.44%
Peripheral Interventions
698.00M
13.79%
Urology
676.00M
13.36%
Andere
1.38B
27.25%
Aktionärsstatistik
Aktualisiert: Sat, Nov 8
Aktualisiert: Sat, Nov 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.28%
Fidelity Management & Research Company LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.37%
State Street Investment Management (US)
4.38%
PRIMECAP Management Company
2.23%
Andere
72.63%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.28%
Fidelity Management & Research Company LLC
6.11%
BlackRock Institutional Trust Company, N.A.
5.37%
State Street Investment Management (US)
4.38%
PRIMECAP Management Company
2.23%
Andere
72.63%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
50.76%
Investment Advisor/Hedge Fund
29.08%
Hedge Fund
4.91%
Pension Fund
2.94%
Research Firm
2.73%
Bank and Trust
1.89%
Sovereign Wealth Fund
1.58%
Family Office
0.23%
Private Equity
0.18%
Andere
5.69%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
2858
1.40B
94.34%
-402.85K
2025Q3
2905
1.40B
94.56%
+9.92M
2025Q2
2818
1.39B
94.08%
+7.87M
2025Q1
2724
1.38B
93.98%
-8.23M
2024Q4
2559
1.38B
93.68%
+12.79M
2024Q3
2401
1.36B
94.13%
-3.01M
2024Q2
2325
1.37B
94.20%
+2.64M
2024Q1
2212
1.37B
95.15%
-32.63M
2023Q4
2153
1.38B
96.34%
-8.17M
2023Q3
2083
1.39B
95.41%
+17.41M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
136.47M
9.21%
+2.53M
+1.89%
Jun 30, 2025
Fidelity Management & Research Company LLC
99.47M
6.71%
-17.98M
-15.31%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
78.19M
5.28%
+380.40K
+0.49%
Jun 30, 2025
State Street Investment Management (US)
65.19M
4.4%
+713.38K
+1.11%
Jun 30, 2025
PRIMECAP Management Company
34.66M
2.34%
-1.83M
-5.03%
Jun 30, 2025
Geode Capital Management, L.L.C.
32.42M
2.19%
+622.60K
+1.96%
Jun 30, 2025
Capital World Investors
28.52M
1.93%
-33.95K
-0.12%
Jun 30, 2025
Managed Account Advisors LLC
22.05M
1.49%
+765.61K
+3.60%
Jun 30, 2025
The Bollard Group, LLC
20.08M
1.36%
-411.38K
-2.01%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
19.46M
1.31%
-275.11K
-1.39%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Mon, Dec 1
Aktualisiert: Mon, Dec 1
Name
Anteil
iShares U.S. Medical Devices ETF
12.15%
Goldman Sachs Future Health Care Equity ETF
8.33%
Invesco Dorsey Wright Healthcare Momentum ETF
3.87%
Tema Heart & Health ETF
3.66%
First Trust Bloomberg R&D Leaders ETF
3.14%
Parnassus Core Select ETF
3.1%
WisdomTree US AI Enhanced Value Fund
3.1%
Health Care Select Sector SPDR Fund
3.06%
Global X Aging Population ETF
2.99%
Proshares Ultra Health Care
2.95%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil12.15%
Goldman Sachs Future Health Care Equity ETF
Anteil8.33%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil3.87%
Tema Heart & Health ETF
Anteil3.66%
First Trust Bloomberg R&D Leaders ETF
Anteil3.14%
Parnassus Core Select ETF
Anteil3.1%
WisdomTree US AI Enhanced Value Fund
Anteil3.1%
Health Care Select Sector SPDR Fund
Anteil3.06%
Global X Aging Population ETF
Anteil2.99%
Proshares Ultra Health Care
Anteil2.95%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Boston Scientific Corp?
Die fünf größten Anteilseigner von Boston Scientific Corp sind:
The Vanguard Group, Inc. hält 136.47M Aktien, was 9.21% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 99.47M Aktien, was 6.71% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 78.19M Aktien, was 5.28% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 65.19M Aktien, was 4.40% der Gesamtaktien entspricht.
PRIMECAP Management Company hält 34.66M Aktien, was 2.34% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 136.47M Aktien, was 9.21% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 99.47M Aktien, was 6.71% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 78.19M Aktien, was 5.28% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 65.19M Aktien, was 4.40% der Gesamtaktien entspricht.
PRIMECAP Management Company hält 34.66M Aktien, was 2.34% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Boston Scientific Corp?
Die drei wichtigsten Anteilseigner-Typen von Boston Scientific Corp sind:
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
BlackRock Institutional Trust Company, N.A.
Wie viele Institutionen halten Anteile an Boston Scientific Corp (BSX)?
Mit Stand vom 2025Q4 halten 2858 Institutionen Anteile an Boston Scientific Corp, mit einem Gesamtmarktwert von etwa 1.40B, was 94.34% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -0.23% gestiegen.
Was ist die größte Einnahmequelle von Boston Scientific Corp?
Am FY2025Q2 erzielte das Geschäft mit Electrophysiology für Boston Scientific Corp den höchsten Umsatz in Höhe von 840.00M, was 16.60% des Gesamtumsatzes entspricht.
